Tafamidis

Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce disease progression and mortality significantly. This activity will highlight the current indications, mechanism of action, dosage, contraindications, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) of tafamidis in a clinical setting pertinent for healthcare team members in the management of patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) or peripheral neuropathy (ATTR-PN).

Provider:StatPearls, LLC
Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/137853
Start Date: 2023-09-01 05:00:00
End Date: 2023-09-01 05:00:00
Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours
MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABTS - 1.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABTS - 1.0 Point; Credit Type(s): Self-Assessment (ABTS)
Commercial Support: No
Activity Type: Enduring Material
CME Finder Type: Online Learning
Fee to Participate: Variable
Measured Outcome: Learner Knowledge, Learner/Team Competence
Provider Ship: Directly Provided
Registration: Open to all
Specialty: Adult Cardiac, Advanced Heart Failure and Transplant Cardiology, Ambulatory/Outpatient, Cardiothoracic, Cardiovascular, Cardiovascular Disease, Chemical Pathology, Critical Care Medicine, General Operative Anesthesia, General Surgery, Geriatric Medicine, Hematology, Hospital Medicine, Internal Medicine, Medical Oncology, Molecular Genetic Pathology, Nephrology, Pulmonary Disease, Rheumatology

Contact us

Sign up for the expert list